Tabula Rasa HealthCare (TRHC) Director Bruce Luehrs Sells 67,569 Shares

Tabula Rasa HealthCare (NASDAQ:TRHC) Director Bruce Luehrs sold 67,569 shares of the firm’s stock in a transaction dated Tuesday, May 15th. The shares were sold at an average price of $47.99, for a total value of $3,242,636.31. The sale was disclosed in a legal filing with the SEC, which is available at this link.

Bruce Luehrs also recently made the following trade(s):

  • On Thursday, May 17th, Bruce Luehrs sold 32,431 shares of Tabula Rasa HealthCare stock. The shares were sold at an average price of $49.16, for a total value of $1,594,307.96.
  • On Tuesday, March 20th, Bruce Luehrs sold 12,234 shares of Tabula Rasa HealthCare stock. The shares were sold at an average price of $38.01, for a total value of $465,014.34.
  • On Tuesday, March 13th, Bruce Luehrs sold 16,745 shares of Tabula Rasa HealthCare stock. The shares were sold at an average price of $37.63, for a total value of $630,114.35.
  • On Friday, March 9th, Bruce Luehrs sold 15,664 shares of Tabula Rasa HealthCare stock. The shares were sold at an average price of $37.09, for a total value of $580,977.76.
  • On Tuesday, March 6th, Bruce Luehrs sold 3,115 shares of Tabula Rasa HealthCare stock. The shares were sold at an average price of $36.03, for a total value of $112,233.45.
  • On Thursday, February 22nd, Bruce Luehrs sold 252,242 shares of Tabula Rasa HealthCare stock. The shares were sold at an average price of $34.29, for a total value of $8,649,378.18.

TRHC stock opened at $50.39 on Friday. The company has a current ratio of 0.45, a quick ratio of 0.41 and a debt-to-equity ratio of 0.01. Tabula Rasa HealthCare has a 52-week low of $47.61 and a 52-week high of $48.69. The company has a market cap of $972.49 million, a price-to-earnings ratio of -1,259.75, a price-to-earnings-growth ratio of 4.34 and a beta of 2.38.

Tabula Rasa HealthCare (NASDAQ:TRHC) last posted its quarterly earnings data on Tuesday, May 8th. The company reported $0.10 earnings per share (EPS) for the quarter. Tabula Rasa HealthCare had a positive return on equity of 0.38% and a negative net margin of 0.61%. The company had revenue of $43.94 million for the quarter, compared to the consensus estimate of $42.60 million. During the same period in the previous year, the business earned $0.08 EPS. Tabula Rasa HealthCare’s revenue for the quarter was up 57.0% compared to the same quarter last year. equities analysts forecast that Tabula Rasa HealthCare will post 0.45 EPS for the current fiscal year.

A number of hedge funds have recently bought and sold shares of the business. BlackRock Inc. increased its holdings in Tabula Rasa HealthCare by 284.6% during the 1st quarter. BlackRock Inc. now owns 1,634,528 shares of the company’s stock worth $63,419,000 after purchasing an additional 1,209,501 shares during the last quarter. Hood River Capital Management LLC increased its holdings in shares of Tabula Rasa HealthCare by 1.2% in the 1st quarter. Hood River Capital Management LLC now owns 893,843 shares of the company’s stock valued at $34,681,000 after acquiring an additional 10,553 shares during the last quarter. Ranger Investment Management L.P. increased its holdings in shares of Tabula Rasa HealthCare by 896.7% in the 4th quarter. Ranger Investment Management L.P. now owns 777,341 shares of the company’s stock valued at $21,804,000 after acquiring an additional 699,352 shares during the last quarter. Jennison Associates LLC increased its holdings in shares of Tabula Rasa HealthCare by 3.5% in the 4th quarter. Jennison Associates LLC now owns 412,387 shares of the company’s stock valued at $11,567,000 after acquiring an additional 13,932 shares during the last quarter. Finally, UBS Asset Management Americas Inc. bought a new stake in shares of Tabula Rasa HealthCare in the 4th quarter valued at approximately $9,559,000. Institutional investors own 49.48% of the company’s stock.

Several brokerages recently commented on TRHC. Zacks Investment Research upgraded Tabula Rasa HealthCare from a “sell” rating to a “buy” rating and set a $53.00 target price on the stock in a report on Tuesday. Piper Jaffray reiterated an “overweight” rating and set a $46.00 target price on shares of Tabula Rasa HealthCare in a report on Wednesday, May 9th. Citigroup reiterated a “buy” rating and set a $57.00 target price on shares of Tabula Rasa HealthCare in a report on Wednesday, May 9th. ValuEngine upgraded Tabula Rasa HealthCare from a “hold” rating to a “buy” rating in a report on Wednesday, May 2nd. Finally, BidaskClub upgraded Tabula Rasa HealthCare from a “buy” rating to a “strong-buy” rating in a report on Tuesday, April 24th. One research analyst has rated the stock with a hold rating, twelve have assigned a buy rating and one has issued a strong buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average target price of $39.91.

About Tabula Rasa HealthCare

Tabula Rasa HealthCare, Inc operates as a healthcare technology company in the United States. It offers medication risk management, pharmacy cost management, and medicare risk adjustment services. The company offers its technology-enabled products and services to prescribers, pharmacists, and healthcare organizations for medication risk management and risk adjustment.

Insider Buying and Selling by Quarter for Tabula Rasa HealthCare (NASDAQ:TRHC)

Receive News & Ratings for Tabula Rasa HealthCare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tabula Rasa HealthCare and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply